Equity Overview
Price & Market Data
Price: $4.47
Daily Change: +$0.04 / 0.89%
Daily Range: $4.34 - $4.60
Market Cap: $32,119,656
Daily Volume: 7,924
Performance Metrics
1 Week: 7.26%
1 Month: 14.77%
3 Months: -42.09%
6 Months: -66.13%
1 Year: -88.52%
YTD: -37.69%
Company Details
Employees: 17
Sector: Health technology
Industry: Biotechnology
Country: Canada
Details
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the
clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.